Skip to Content

'
Liana Adam, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Urology - Research, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Assistant Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1996 Universite Paris-Nord (Paris XIII), Paris, France, PHD, Biochemistry and Cell Biology
1995 Universite Rene Descartes (Paris V), Paris, France, Residency, Chemotherapy
1994 Institute Pasteur, Paris, France, MS, Cell and Molecular Biology
1992 Universite Paris-Nord, Paris, France, MS, Biochemical Sciences
1987 University of Medicine, Iasi, Romania, MD, Medicine

Experience/Service

Academic Appointments

Instructor, Department of Urology - Research, The University of Texas M. D. Anderson Cancer Center, Urology Research, Houston, TX, 1/2003-1/2004
Research Associate, Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1/1999-1/2002
Postdoctoral Fellow, Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1997-1999
Postdoctoral Fellow, Institute of Oncology Gustave Roussy-Villejuif, Paris, France, 1/1996-1/1997
PhD Trainee, Institut d'Oncologie Moleculaire & Cellulaire Humaine, Paris, France, 1/1991-1/1996
Medical Doctor, Municipal Hospital of Timisoara, Timisoara, Romania, 1/1987-1/1990

Selected Publications

Peer-Reviewed Original Research Articles
1. Betty C. Rostro-Kohanloo, Lissett R. Bickford, Courtney M. Payne, Emily S. Day, Lindsey J. E. Stabilization and Targeting of Surfactant-Synthesized Gold Nanorods. Nanotechnology. In Press.
2. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy. Clin Cancer Res 15(16). e-Pub 8/11/2009. PMID: 19671845.
3. Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 15(20):2288-99, 2009. PMID: 19601831.
4. Molli PR, Adam L, Kumar R. Therapeutic IMC-C225 antibody inhibits breast cancer cell invasiveness via Vav2-dependent activation of RhoA GTPase. Clin Cancer Res 14(19):6161-6170, 10/2008.
5. Kassouf W, Brown GA, Black PC, Fisher MB, Inamoto T, Luongo T, Gallagher D, Bar-Eli M, McConkey DJ, Adam L, Dinney CPN. Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer. Journal of Urology 180(3):1146-1153, 9/2008.
6. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 14(5):1478-86, 3/1/2008. PMID: 18316572.
7. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 179(1):353-8, 1/2008. PMID: 18006009.
8. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ, McCarty M, Adam L, Bar-Eli M. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 26(28):4049-58, 6/14/2007. PMID: 17224907.
9. Adam L, Black PC, Kassouf W, Eve B, McConkey D, Munsell MF, Benedict WF, Dinney CP. Adenoviral mediated interferon-alpha 2b gene therapy suppresses the pro-angiogenic effect of vascular endothelial growth factor in superficial bladder cancer. J Urol 177(5):1900-6, 5/2007. PMID: 17437845.
10. Shrader M, Pino MS, Lashinger L, Bar-Eli M, Adam L, Dinney CP, McConkey DJ. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 67(4)(4):1430-5, 2/2007. PMID: 17308080.
11. Shrader M, Pino MS, Brown G, Black P, Adam L, Bar-Eli M, Dinney CP, McConkey DJ. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 6(1):277-85, 1/2007. PMID: 17237287.
12. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, Aldape KD, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 12(15):4671-7, 8/2006. PMID: 16899617.
13. Kassouf W, Luongo T, Brown G, Adam L, Dinney CP. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 176(2):787-92, 8/2006. PMID: 16813948.
14. Kassouf W, Dinney CP, Brown G, McConkey DJ, Diehl AJ, Bar-Eli M, Adam L. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res 65(22):10524-35, 11/2005. PMID: 16288045.
15. Adam L, Kassouf W, Dinney CP. Clinical applications for targeted therapy in bladder cancer. Urol Clin North Am 32(2):239-46, vii, 5/2005. PMID: 15862621.
16. Benedict WF, Tao Z, Kim CS, Zhang X, Zhou JH, Adam L, McConkey DJ, Papageorgiou A, Munsell M, Philopena J, Engler H, Demers W, Maneval DC, Dinney CP, Connor RJ. Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein. Mol Ther 10(3):525-32, 9/2004. PMID: 15336652.
17. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 8/2004. PMID: 15324694.
18. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, Clayman GL, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res 10(2):658-67, 1/2004. PMID: 14760089.
19. Vadlamudi RK, Sahin AA, Adam L, Wang RA, Kumar R. Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215. FEBS Lett 543(1-3):76-80, 5/2003. PMID: 12753909.
20. Vadlamudi RK, Li F, Adam L, Nguyen D, Ohta Y, Stossel TP, Kumar R. Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 4(9):681-90, 9/2002. PMID: 12198493.
21. Kumar R, Wang RA, Mazumdar A, Talukder AH, Mandal M, Yang Z, Bagheri-Yarmand R, Sahin A, Hortobagyi G, Adam L, Barnes CJ, Vadlamudi RK. A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature 418(6898):654-7, 8/2002. PMID: 12167865.
22. Li F, Adam L, Vadlamudi RK, Zhou H, Sen S, Chernoff J, Mandal M, Kumar R. p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep 3(8):767-73, 8/2002. PMID: 12151336.
23. Song RX, Santen RJ, Kumar R, Adam L, Jeng MH, Masamura S, Yue W. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 193(1-2):29-42, 7/2002. PMID: 12160999.
24. Vadlamudi RK, Adam L, Nguyen D, Santos M, Kumar R. Differential regulation of components of the focal adhesion complex by heregulin: role of phosphatase SHP-2. J Cell Physiol 190(2):189-99, 2/2002. PMID: 11807823.
25. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol 80(2):239-56, 2/2002. PMID: 11897507.
26. Song RX, McPherson RA, Adam L, Bao Y, Shupnik M, Kumar R, Santen RJ. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol Endocrinol 16(1):116-27, 2002. PMID: 11773443.
27. Adam L, Vadlamudi RK, McCrea P, Kumar R. Tiam1 overexpression potentiates heregulin-induced lymphoid enhancer factor-1/beta -catenin nuclear signaling in breast cancer cells by modulating the intercellular stability. J Biol Chem 276(30):28443-50, 7/2001. PMID: 11328805.
28. Adam L, Mazumdar A, Sharma T, Jones TR, Kumar R. A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res 61(1):81-7, 2001. PMID: 11196203.
29. Mazumdar A, Adam L, Boyd D, Kumar R. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. Cancer Res 61(1):400-5, 2001. PMID: 11196194.
30. Mazumdar A, Wang RA, Mishra SK, Adam L, Bagheri-Yarmand R, Mandal M, Vadlamudi RK, Kumar R. Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nat Cell Biol 3(1):30-7, 2001. PMID: 11146623.
31. Kumar R, Vadlamudi RK, Adam L. Apoptosis in mammary gland and cancer. Endocr Relat Cancer 7(4):257-69, 12/2000. PMID: 11174847.
32. Vadlamudi RK, Wang RA, Talukder AH, Adam L, Johnson R, Kumar R. Evidence of Rab3A expression, regulation of vesicle trafficking, and cellular secretion in response to heregulin in mammary epithelial cells. Mol Cell Biol 20(23):9092-101, 12/2000. PMID: 11074007.
33. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J, Hung MC, Kumar R. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 275(46):36238-44, 11/2000. PMID: 10945974.
34. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. P21-activated-1 kinase regulates microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 275:12041-50, 4/2000. PMID: 10766836.
35. Talukder AH, Adam L, Raz A, Kumar R. Heregulin regulation of autocrine motility factor expression in human tumor cells. Cancer Res 60(2):474-80, 1/2000. PMID: 10667603.
36. Adam L, Bandyopadhyay D, Kumar R. Interferon-alpha signaling promotes nucleus-to-cytoplasmic redistribution of p95Vav, and formation of a multisubunit complex involving Vav, Ku80, and Tyk2. Biochem Biophys Res Commun 267(3):692-6, 1/2000. PMID: 10673353.
37. Vadlamudi R, Adam L, Talukder A, Mendelsohn J, Kumar R. Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase. Oncogene 18(51):7253-64, 12/1999. PMID: 10602479.
38. Mandal M, Adam L, Kumar R. Redistribution of activated caspase-3 to the nucleus during butyric acid-induced apoptosis. Biochem Biophys Res Commun 260(3):775-80, 7/1999. PMID: 10403841.
39. Vadlamudi R, Adam L, Tseng B, Costa L, Kumar R. Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells. Cancer Res 59(12):2843-6, 6/1999. PMID: 10383144.
40. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18(2):305-14, 1/1999. PMID: 9927187.
41. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273(43):28238-46, 10/1998. PMID: 9774445.
42. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 17(8):999-1007, 8/1998. PMID: 9747879.
43. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 273(3):1568-73, 1/1998. PMID: 9430697.
44. Kumar R, Mandal M, Steinbach G, Adam L. Short-chain fatty acids regulate the motility of human carcinoma cells. Gastroenterology 114(4):A781-A781, Part 2, Suppl., 1998.
45. Adam L, Crépin M, Israèl L. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and Tamoxifen combination. Cancer Res 57:1023-1029, 1997.
46. Adam L, Crépin M, Savin C, Israèl L. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in Mcf-7ras cells in vitro and in nude mice. Cancer Res 55:5156-5160, 1995.
47. Adam L, Moliard M, Breau JL, Crépin M, Israèl L. Composante stromale et facteurs pronostiques dans le cancer du sein (in French). Cahiers d’Oncologie 3:9-15, 1994.
48. Adam L, Crépin M, Lelong JC, Koumdjian JC, Spanakis E, Israèl L. Selective interactions between mammary epithelial cells and fibroblasts in co-culture. Int J Cancer 59:262-270, 1994.
49. Rovigatti U Adam L Crepin M. Un gene cle des cancers : p53. Review (in French). Cahiers d’Oncologie 1:205-212, 1992.

Last updated: 9/23/2009